Shapiro, Geoffrey I <br/><br/>
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jan 2014 
 - 233-45 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-13-1777  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Area Under Curve<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Phosphatidylinositol 3-Kinase--metabolism<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Quinoxalines--administration & dosage<br/>Signal Transduction<br/>Skin Diseases--chemically induced<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome